Yidong Wei | Immunology Cellular Interactions | Best Researcher Award

Published on by Cell Biologist

Prof. Yidong Wei | Immunology Cellular Interactions | Best Researcher Award

Prof. Yidong Wei , Shanghai Tenth People’s Hospital, Tongji University , China

Dr. Yidong Wei, M.D., Ph.D., FACC, is a distinguished professor and the Chief of Cardiology at Shanghai Tenth People’s Hospital, Tongji University. He also holds a clinician management role at the Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford. With a strong foundation in both clinical and translational research, Dr. Wei has built an internationally recognized career focused on interventional cardiology, cardiac electrophysiology, and cardiovascular epidemiology. He is a Fellow of the American College of Cardiology, reflecting his global academic influence. Known for bridging clinical care with bench-side discovery, his work has advanced understanding in myocardial infarction, heart failure, and calcium signaling in cardiomyocytes. With numerous high-impact publications and leadership in multicenter registries like NOAFCAMI-SH, Dr. Wei’s contributions are widely cited and clinically relevant. His dual academic and clinical roles across China and the UK highlight his dedication to innovation, international collaboration, and excellence in cardiovascular medicine.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. High-Impact Research Output:
    Dr. Wei has authored or co-authored more than 18 recent peer-reviewed publications in prestigious journals such as Diabetes Metabolism Research and Reviews, Redox Biology, Cardiovascular Diabetology, and ESC Heart Failure. Many of these works are already cited, indicating early academic impact and relevance.

  2. Dual Focus – Basic and Clinical Science:
    His research bridges the gap between molecular mechanisms (e.g., calcium signaling, TRIM21, PTEN) and clinical cardiology (e.g., atrial fibrillation, myocardial infarction, cardiac remodeling), highlighting a robust translational focus.

  3. Leadership and Collaboration:
    He serves as Chief of Cardiology at Shanghai Tenth People’s Hospital and a Clinician Manager at the University of Oxford, demonstrating international leadership and cross-border collaboration.

  4. Registry Leadership (NOAFCAMI-SH):
    His work through the NOAFCAMI-SH registry provides real-world evidence on cardiovascular disease progression, risk prediction, and treatment response—critical for patient-centered care.

  5. Prestigious Recognition:
    Dr. Wei is a Fellow of the American College of Cardiology (FACC), a title reserved for top-tier cardiovascular professionals with sustained excellence.

⚠️ Areas for Improvement:

  1. Broader International Research Leadership:
    While Dr. Wei has strong China–UK collaborations, leading global multicenter clinical trials or international consortia would further solidify his standing.

  2. Public Engagement and Knowledge Translation:
    Though academically prolific, increased involvement in public health education or policy advocacy could amplify the real-world impact of his research.

  3. Mentorship Track Record Visibility:
    Highlighting mentorship of junior researchers and postdocs more explicitly in profiles and bios would enhance his case for a holistic academic leadership award.

🎓 Education:

Dr. Wei began his medical education at Henan Medical University, where he completed clinical training with a focus on cardiovascular medicine. Driven by a passion for research, he pursued and completed his Ph.D. in 2004, with a specialization in cardiac electrophysiology and calcium signaling pathways. His graduate studies were complemented by advanced basic science training at the University of Kentucky, USA, a leading institution in biomedical research. Between 2004 and 2006, Dr. Wei completed postdoctoral research, focusing on the molecular mechanisms of cardiac dysfunction and electrophysiology. His educational background reflects a balanced integration of rigorous clinical education and innovative research development, equipping him with the tools necessary to bridge bedside care with laboratory insights. This foundation has allowed Dr. Wei to contribute to both academic medicine and cutting-edge cardiovascular research, distinguishing him as a leader with comprehensive and global training in the field.

🏥 Experience:

With over two decades of experience, Dr. Yidong Wei serves as Professor and Chief of the Department of Cardiology at Shanghai Tenth People’s Hospital, Tongji University. His role extends internationally, acting as Clinician Manager at the University of Oxford’s Centre for Diabetes, Endocrinology and Metabolism. His clinical expertise spans interventional cardiology, acute coronary syndromes, and electrophysiological interventions, while his research roles emphasize trial design, biomarker discovery, and cellular cardiology. He has led and contributed to large-scale registries like NOAFCAMI-SH, generating evidence that informs guidelines for myocardial infarction and atrial fibrillation. His professional experience combines healthcare leadership, cross-border academic collaboration, and impactful research. As a Fellow of the American College of Cardiology, he is actively engaged in academic societies and peer-reviewed journals. Dr. Wei’s experience reflects an enduring commitment to patient care, innovation in research, and mentorship of future cardiology leaders, marking him as a high-impact contributor in his field.

🔬 Research Focus:

Dr. Yidong Wei’s research lies at the intersection of clinical cardiology and molecular medicine. He focuses on interventional cardiology, atrial fibrillation, myocardial infarction, and calcium signaling pathways in cardiac myocytes. A major theme in his work is the electrophysiological basis of heart failure and age-related changes in ventricular function. Using techniques like patch clamping, calcium imaging, laser confocal microscopy, and molecular biology, he investigates calcium channel regulation and excitation-contraction coupling in cardiac cells. Clinically, he leads research through the NOAFCAMI-SH registry, analyzing systemic inflammation, hyperglycemia, atrial fibrillation, and long-term cardiac outcomes. His work advances the understanding of post-infarction remodeling and atrial pathology. Combining basic science with real-world data, Dr. Wei’s research bridges gaps in translational cardiology and offers therapeutic targets for chronic cardiac conditions. His integrative approach makes him a pioneer in translating bench findings into bedside impact, with potential to redefine cardiac care strategies globally.

📚 Publications Top Notes:

  1. 📈 Association of stress hyperglycemia ratio with atrial fibrillation and outcomes in myocardial infarction

  2. 🧪 Prognostic implications of systemic immune-inflammation index in MI patients with and without diabetes

  3. 🧬 TRIM21 deficiency protects heart post-MI by reducing oxidative stress

  4. 🫀 4S-AF scheme for characterizing atrial fibrillation after myocardial infarction

  5. 🔬 TRIM21 worsens cardiac injury via M1 macrophage polarization post-MI

  6. 🧮 Stress hyperglycemia and outcomes in MI with and without diabetes mellitus

  7. 💉 ZPI protects endothelium via PI3K/Akt pathway activation against ox-LDL

  8. 📊 Atrial fibrillation’s prognosis across heart failure subtypes post-MI

  9. 🕒 Five-year outcomes post left atrial appendage occlusion

  10. 🧫 PTEN and serum deprivation-induced cytotoxicity via PI3K/AKT pathway

🧾 Conclusion:

Dr. Yidong Wei stands out as a highly suitable candidate for the Best Researcher Award. His contributions to cardiovascular research—spanning cutting-edge basic science to influential clinical trials—are both innovative and impactful. His leadership roles, international presence, and translational focus align perfectly with the goals of this prestigious recognition. Given his trajectory, Dr. Wei is not only a leader in current cardiovascular research but also a driver of future scientific breakthroughs.

Chao Weng | Immunology Cellular Interactions | Best Researcher Award

Published on by Cell Biologist

Mr. Chao Weng | Immunology Cellular Interactions | Best Researcher Award

Mr. Chao Weng , Renmin Hospital of Wuhan University , China

Dr. Chao Weng is an Associate Chief Physician at Renmin Hospital of Wuhan University. With both an MD and a Ph.D. from Wuhan University, he further advanced his expertise through two years of research at McGill University, Canada. Specializing in neuroimmune diseases, Dr. Weng is proficient in diagnosing and treating conditions such as multiple sclerosis, myasthenia gravis, and Guillain-Barré syndrome. His prolific career spans over 40 published papers, including nearly 20 SCI-indexed articles. Dr. Weng has contributed significantly to scientific research with over nine research projects, including international collaborations, and has been awarded national patents and honors. He is an active member of prominent neurological associations, including the Neurology Branch of the China Association for the Promotion of International Exchange in Healthcare and the Wuhan Electroencephalography and Neurophysiology Association.

Publication Profile:

Orcid

Strengths for the Award:

Dr. Chao Weng is an accomplished researcher and clinician, demonstrating significant contributions to the field of neuroimmune diseases, particularly multiple sclerosis, myasthenia gravis, and Guillain-Barré syndrome. His expertise in molecular mechanisms, particularly in myelin development and regeneration, is groundbreaking, as reflected in his research projects funded by prestigious organizations such as the National Natural Science Foundation of China and the Multiple Sclerosis Society of Canada. He has published over 40 academic papers, including nearly 20 SCI papers, and is actively involved in high-impact research on transcription factors, gene mutations, and the pathogenesis of various neurological conditions. His work on promoting oligodendrocyte differentiation and remyelination is highly relevant to advancing treatments for neuroimmune diseases.

In addition to his strong publication record, Dr. Weng’s leadership in hosting and participating in multiple scientific research projects, alongside his involvement in clinical education and professional organizations, demonstrates his multifaceted impact on the field. His contributions have been recognized with awards such as the second prize for scientific and technological progress in Hubei Province and a national invention patent. Furthermore, his collaborations with prestigious institutions like McGill University enhance the international scope of his work.

Areas for Improvement:

Although Dr. Weng’s research achievements are significant, continued engagement with broader interdisciplinary collaborations could further enhance the impact of his work. Integrating new technologies or methodologies in neuroimmune disease diagnostics and treatment, such as artificial intelligence or advanced imaging techniques, could provide additional depth to his ongoing projects. Furthermore, further outreach through mentorship of younger researchers could help cultivate the next generation of scientists and clinicians in his area of expertise. Expanding industry collaborations could also provide more avenues for the translation of research into clinical practice.

Education:

Dr. Chao Weng completed his MD and Ph.D. at Wuhan University, where he focused on neuroimmune diseases. Afterward, he expanded his knowledge by studying abroad at McGill University in Canada for two years. His education provided him with a strong foundation in both clinical practice and research in neuroimmunology, especially related to diseases like multiple sclerosis, myasthenia gravis, and Guillain-Barré syndrome. At Wuhan University, Dr. Weng honed his expertise in molecular mechanisms of neuroimmune diseases and remyelination. His ongoing commitment to furthering scientific research in neurology and neuroimmunology has kept him at the forefront of cutting-edge advancements in his field, including in vitro human and mouse oligodendrocyte culture and transcription factor Tcf7l2’s role in oligodendrocyte differentiation.

Experience:

Dr. Chao Weng has extensive experience in the clinical diagnosis and treatment of neuroimmune diseases, particularly focusing on conditions like multiple sclerosis, myasthenia gravis, and Guillain-Barré syndrome. Over the years, he has been actively involved in scientific research, completing and overseeing numerous research projects. He has led nine major scientific research projects, including collaborations with international research institutions like McGill University, Canada. Dr. Weng has published over 40 academic papers, including 20 SCI papers, contributing to the understanding of neuroimmune diseases, myelin repair, and neurodegeneration. His involvement in high-impact research, such as studying transcription factors for oligodendrocyte differentiation and remyelination, and investigating molecular mechanisms in neurological diseases, demonstrates his dedication to advancing both basic and clinical research. Additionally, he is a respected member of various neurological organizations and has received significant recognition for his scientific achievements.

Awards and Honors:

Dr. Chao Weng has earned numerous accolades for his scientific contributions, including a second prize for scientific and technological progress in Hubei Province. His groundbreaking research in neuroimmune diseases and oligodendrocyte differentiation has garnered recognition in the academic community, where he has published more than 40 peer-reviewed papers, nearly 20 of them indexed in SCI. Dr. Weng has also been awarded a national invention patent, underscoring his innovative contributions to medical science. His commitment to advancing medical knowledge and improving patient outcomes in neuroimmune diseases has positioned him as a leader in his field. His recognition extends to his role as a director of the Wuhan Electroencephalography and Neurophysiology Association and a member of the Neurology Branch of the China Association for the Promotion of International Exchange in Healthcare, which further highlights his influence and standing in the scientific and medical community.

Research Focus:

Dr. Chao Weng’s primary research focus lies in neuroimmune diseases, specifically exploring the molecular mechanisms underlying diseases like multiple sclerosis, myasthenia gravis, and Guillain-Barré syndrome. His work emphasizes remyelination, the repair of myelin in neurodegenerative diseases, and the role of oligodendrocyte differentiation in central nervous system regeneration. He has spent nearly a decade investigating transcription factor Tcf7l2’s impact on myelin development and regeneration. Dr. Weng has also made significant contributions to understanding the role of β-arrestin 2 in protecting against neurological defects induced by viral infections such as herpes simplex encephalitis. Additionally, his research covers the therapeutic potential of neurotrophic factors and ion channels in various neurological disorders, including Parkinson’s disease and epilepsy. Through his work, Dr. Weng has become a key figure in bridging basic neuroscience with clinical applications, aiming to enhance diagnostic and therapeutic strategies for patients suffering from neuroimmune conditions.

Publications Top Notes:

  1. Transcription factor 7 like 2 promotes oligodendrocyte differentiation and remyelination 🧠
  2. Screening Gene Mutations in Chinese Patients With Benign Essential Blepharospasm 🔬
  3. β-Arrestin 2 protects against neurological function defects in HSV-1-induced encephalitis mice 🦠
  4. Inhibition of Acid Sensing Ion Channel 3 Aggravates Seizures by Regulating NMDAR Function ⚡
  5. Purkinje Cell Degeneration and Motor Coordination Deficits in a New Mouse Model of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay 🧑‍🔬
  6. Ankfy1 is dispensable for neural stem/precursor cell development 🧬
  7. Clinical and electrophysiological evaluation of neutral wrist nocturnal splinting in patients with carpal tunnel syndrome 🤕
  8. Ring finger sensory latency difference in the diagnosis and treatment of carpal tunnel syndrome 💡
  9. Multiple and short-range cross-linking of dialdehyde carboxymethyl cellulose contributes to regulating the physicochemical property of collagen fibril 🔗
  10. Chronic inflammatory demyelinating polyneuropathy and psoriasis comorbidity with significantly alleviated symptoms after secukinumab 💊

Conclusion:

Dr. Chao Weng is undoubtedly a strong candidate for the Best Researcher Award. His consistent dedication to advancing the understanding of neuroimmune diseases, coupled with his significant contributions to the molecular mechanisms of myelin repair and regeneration, positions him as an exceptional researcher. His multidisciplinary research approach, coupled with his numerous publications and scientific innovations, speaks to his outstanding capability in the field. With continued growth in interdisciplinary collaboration and industry partnerships, Dr. Weng is well-placed to continue making profound contributions to neurology and neuroimmune disease treatments.

Mehmet Ali Karaselek | Immunology | Best Researcher Award

Published on by Cell Biologist

Dr. Mehmet Ali Karaselek | Immunology | Best Researcher Award

Dr. Mehmet Ali Karaselek , Necmettin Erbakan Üniversitesi , Turkey

Dr. Mehmet Ali Karaselek is an accomplished immunologist, widely known for his work on genetic immunodeficiencies and immune system disorders. He holds a significant position in clinical immunology, focusing on T-cell subsets, immune profiling, and the molecular mechanisms behind various immune diseases. His expertise extends to autoimmune diseases, cancers, and rare immunodeficiencies such as ICF syndrome, DCLRE1C deficiency, and CD19 deficiency. His extensive research has contributed to a deeper understanding of immune system dysfunctions and therapeutic implications, especially in immune deficiency conditions. Dr. Karaselek is also involved in training future scientists and physicians, combining his expertise in molecular immunology with clinical practice to improve diagnostic and therapeutic approaches in immunology. His publications and ongoing research projects continue to enrich the field of clinical immunology and immunogenetics.

Publication Profile:

Orcid

Strengths for the Award:

  1. Expertise in Immunology: Dr. Karaselek has contributed significantly to understanding immune system disorders, particularly immune deficiencies and their relationship with genetic mutations. This is reflected in several of his articles related to immune cell subsets, immune disorders like immunodeficiencies (e.g., CD19 deficiency, DCLRE1C deficiency), and T-cell and NK-cell functions.

  2. Innovative Research Areas: His focus on transcription factor and cytokine expression in various T-cell subsets, as well as his recent work in cancer-related therapies using pillar[5]arene derivatives, illustrates a strong grasp of cutting-edge topics in both immunology and drug development.

  3. Collaboration Across Fields: Dr. Karaselek’s research spans multiple fields, including cancer research, immunodeficiencies, and genetic disorders, showcasing his ability to work across disciplines. He has collaborated with many researchers on complex issues like genetic mutations and immune dysfunctions, highlighting his team-based approach and leadership in the research community.

  4. Contributions to Clinical Immunology: His numerous articles in high-impact journals, such as the Journal of Clinical Immunology, Expert Review of Clinical Immunology, and APMIS, demonstrate his dedication to advancing clinical research, improving diagnostics, and understanding immune system pathologies.

  5. High Publication Frequency: The volume of publications and the consistency of research output in recent years (2023–2025) reflects a high level of productivity and dedication to his field. This output signifies Dr. Karaselek’s capacity to consistently push the boundaries of immunology research.

Areas for Improvement:

  1. Broader Global Recognition: While Dr. Karaselek’s publications are substantial, increasing the international impact of his work through higher-profile collaborations or by engaging in high-impact, globally recognized studies could further elevate his standing in the scientific community.

  2. Interdisciplinary Impact: Although his work covers a broad spectrum, a more explicit focus on interdisciplinary applications of his research, especially between immunology, genomics, and personalized medicine, could help translate his research findings into clinical practice more effectively.

  3. Public Engagement: Engaging in public-facing work such as writing for science outreach or sharing research insights in a more accessible format could further enhance his visibility and allow his discoveries to have a broader societal impact.

Education:

Dr. Mehmet Ali Karaselek earned his medical degree from a prestigious institution, followed by specialized training in clinical immunology. He furthered his education with a focus on advanced immunology and immunogenetics, completing multiple certifications and postdoctoral research programs. His early academic interests were rooted in understanding the molecular basis of immune system disorders, which led him to pursue an in-depth study of genetic immunodeficiencies. He has continually sought to enhance his expertise by participating in various national and international conferences and workshops on immunology. Throughout his career, Dr. Karaselek has combined clinical education with practical experience, which has enabled him to contribute effectively to both scientific research and patient care. His comprehensive educational background has been instrumental in his ability to lead complex research projects, investigate the immunological aspects of rare diseases, and educate others in the field.

Experience:

Dr. Mehmet Ali Karaselek has extensive experience in clinical immunology, with a focus on the genetic and molecular mechanisms of immune disorders. He has worked in academic and clinical settings, leading research projects and contributing to major breakthroughs in immunodeficiencies and autoimmune diseases. Over the years, he has collaborated with a wide range of medical professionals, contributing to the diagnosis and treatment of rare genetic conditions such as ICF syndrome, DCLRE1C deficiency, and CD19 deficiency. His expertise also spans cellular immunology, where he has conducted research on T-cell subsets and cytokine expression. His clinical experience, combined with his research background, has positioned him as a leader in the immunology community, with a focus on improving immunogenetic diagnostic techniques. Dr. Karaselek has also mentored numerous students and professionals, further advancing the field through knowledge dissemination and collaboration.

Research Focus:

Dr. Mehmet Ali Karaselek’s research focuses on the molecular and genetic mechanisms underlying immune system disorders, particularly in the context of immunodeficiencies and autoimmune diseases. He is deeply involved in studying T-cell subsets, immune cell profiling, and cytokine expression in patients with rare genetic mutations. His work has shed light on the pathophysiology of conditions such as ICF syndrome, DCLRE1C deficiency, and CD19 deficiency, with the aim of improving diagnosis and treatment options. Dr. Karaselek is also interested in the immunological aspects of cancer, having explored immune cell interactions in various cancer types. His research contributions extend to immune modulation, studying how intensive physical activity like weightlifting affects immune cells. By integrating clinical observations with laboratory-based research, Dr. Karaselek seeks to bridge the gap between basic science and clinical practice, providing new insights into immune system functionality and dysfunctions.

Publications Top Notes:

  1. Investigation of Transcription Factor and Cytokine Gene Expression Levels in Helper T Cell Subsets Among Turkish Patients Diagnosed with ICF2 and ICF3 Syndrome 🧬🧪
  2. Association of NK cell subsets and cytotoxicity with FCGR3A gene polymorphism in functional NK cell deficiency 🧫🔬
  3. Changes in T-cell subsets occur in interstitial lung disease and may contribute to pathology via complicated immune cascade 🫁🩸
  4. Effect of intensive training on immune system cells in elite female weightlifters 🏋️‍♀️🦠
  5. Evaluation of transcription factors and cytokine expressions of T-cell subsets in CD19 deficiency and their possible relationship with autoimmune disease 🤧🔬
  6. Molecular investigations on T cell subsets in patients affected by hypomorphic DCLRE1C mutation 🧬🔬
  7. Variable clinical presentation of hypomorphic DCLRE1C deficiency from childhood to adulthood 👶👨‍⚕️
  8. Water-soluble Pillar[5]arene-based drug candidates for lung and breast cancer 🧪🌊
  9. Could immune cells be associated with nephropathy in Fabry disease patients? 💉🩺
  10. Effective anticancer agents based-on two Pillar[5]arene derivatives for pancreas cancer cell lines 🧬💊

Conclusion:

Dr. Mehmet Ali Karaselek is a highly qualified and productive researcher with significant contributions in immunology and genetics. His vast experience, innovative approaches, and contributions to key scientific areas make him an ideal candidate for the Researcher for Best Researcher Award. Enhancing his global influence and promoting public engagement in his research would be valuable next steps.